Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
Diabetes Care · 2024
DOI: 10.2337/dc23-1332 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2024. Verfasst von M Sue Kirkman und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of North Carolina at Chapel Hill, Chapel Hill, NC. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemia, Metformin, Sulfonylurea Compounds. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, NHLBI NIH HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE In Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) (5,047 participants, mean follow-up 5.0 years), differences in glycemic control were demonstrated over time among four randomized therapies added to metformin. Weight gain and hypoglycemia are also important outcomes for people with type 2 diabetes. We compared the effects of the four randomized GRADE medications on a composite outcome incorporating glycemic deterioration, weight gain, and hypoglycemia. RESEARCH DESIGN AND METHODS The composite outcome was time to first occurrence of any of the following: HbA1c >7.5%, confirmed; ≥5% weight gain; or severe or recurrent nonsevere hypoglycemia. Secondary analyses included examination of individual components of the composite outcome, subgroup effects and potential mediators, and treatment satisfaction. Cumulative incidence was estimated with the Kaplan-Meier estimator. Cox proportional hazards models were used to assess pairwise group differences in risk of an outcome. RESULTS Risk of reaching the composite outcome (events per 100 participants per treatment year [PTYs]) was lowest with liraglutide (19 per 100 PTYs) followed by sitagliptin (26 per 100 PTYs), glargine (29 per 100 PTYs), and glimepiride (40 per 100 PTYs); all pairwise comparisons were statistically significant. The order was the same for risk of weight gain and hypoglycemia, but risk of glycemic deterioration was lowest with glargine, followed by liraglutide, glimepiride, and sitagliptin. No significant heterogeneity in risk of composite outcome was detected across prespecified covariates. Participants who reached the composite outcome had modestly but significantly lower treatment satisfaction. CONCLUSIONS Among participants treated with common second-line drug classes for type 2 diabetes, the liraglutide group had the lowest and glimepiride the highest risk of reaching a composite outcome encompassing glycemic deterioration, weight gain, and hypoglycemia. These findings may inform decision-making regarding type 2 diabetes therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of North Carolina at Chapel Hill, Chapel Hill, NC.
- The Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, The George Washington University, Rockville, MD.
- Duke University Medical Center, Durham, NC.
- National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Rockville, MD.
- University of New Mexico, Albuquerque, NM.
- Department of Medicine, University of Miami, Miami, FL.
ORCID-Profile: M Sue Kirkman, Heidi Krause-Steinrauf, Ionut Bebu, W Timothy Garvey, Daniel S Hsia, Rodica Pop-Busui
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- NHLBI NIH HHS
- NIGMS NIH HHS
- CDC HHS
- Centers for Disease Control and Prevention
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Heart, Lung, and Blood Institute
Zitieren
APA
Kirkman, M. S., Tripputi, M., Krause-Steinrauf, H., Bebu, I., AbouAssi, H., Burch, H., Duran-Valdez, E., Florez, H., Garvey, W. T., Hsia, D. S., Salam, M., Pop-Busui, R., & GRADE Research Group (2024). Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. https://doi.org/10.2337/dc23-1332
Vancouver
Kirkman MS, Tripputi M, Krause-Steinrauf H, Bebu I, AbouAssi H, Burch H, et al. Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care. 2024. doi:10.2337/dc23-1332
BibTeX
@article{Kirkman2024,
author = {Kirkman, M Sue and Tripputi, Mark and Krause-Steinrauf, Heidi and Bebu, Ionut and AbouAssi, Hiba and Burch, Henry and Duran-Valdez, Elizabeth and Florez, Hermes and Garvey, W Timothy and Hsia, Daniel S and Salam, Maamoun and Pop-Busui, Rodica and GRADE Research Group, GRADE Research Group},
title = {Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)},
journal = {Diabetes Care},
year = {2024},
doi = {10.2337/dc23-1332}
}
EUVIMED